# US 2024/0189261 A1 · Methods and compositions for treating sleep apnea

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189261 A1
- Document ID: US20240189261A1
- Status: Published application
- Kind: A1
- Application number: 18/355,178
- Filed: 2023-07-19
- Published: 2024-06-13
- Earliest claimed: 2017-04-28
- Assignees: The Brigham and Women's Hospital, Inc.
- Applicants: The Brigham and Women's Hospital, Inc.
- Inventors: D. Andrew Wellman; Luigi Taranto-Monternurro
- Web page: https://patentgrep.com/patent/US20240189261A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/222: with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A61K 31/335: having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K 31/381: having five-membered rings
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of a norepinephrine reuptake inhibitor (NRI) and a muscarinic receptor antagonist.

## Claims

### Claim 1

A method of treating a subject having a condition associated with pharyngeal airway collapse while the subject is in a non-fully conscious state, the method comprising administering to a subject in need thereof an effective amount of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a muscarinic receptor antagonist.

### Claim 2 (depends on 1)

The method of claim 1, wherein the NRI is a norepinephrine selective reuptake inhibitor (NSRI).

### Claim 3 (depends on 2)

The method of claim 2, wherein the NSRI is selected from the group consisting of Amedalin, Atomoxetine, CP-39,332, Daledalin, Edivoxetine, Esreboxetine, Lortalamine, Nisoxetine, Reboxetine, Talopram, Talsupram, Tandamine, and Viloxazine.

### Claim 4 (depends on 1)

The method of claim 1, wherein the NRI is a norepinephrine non-selective reuptake inhibitor (NNRI) selected from the group consisting of Amitriptiline, Amoxapine, Bupropion, Ciclazindol, Desipramine, Desvenlafaxine, Dexmethilphenidate, Diethylpropion, Doxepin, Duloxetine, Imipramine, Levomilnacipran, Manifaxine, Maprotiline, Methylphenidate, Milnacipran, Nefazodone, Nortriptyline, Phendimetrazine, Phenmetrazine, Protryptyline, Radafaxine, Tapentadol, Teniloxazine, and Venlafaxine.

### Claim 5 (depends on 1)

The method of claim 1, wherein the NRI is selected from the group consisting of Atomoxetine and Reboxetine.

### Claim 6 (depends on 5)

The method of claim 5, wherein the NRI is Atomoxetine.

### Claim 7 (depends on 6)

The method of claim 6, wherein the Atomoxetine is administered at a dose of 20-100 mg

### Claim 8 (depends on 7)

The method of claim 7, wherein the Atomoxetine is administered at a dose of 25-75 mg.

### Claim 9 (depends on 1)

The method of claim 1, wherein the muscarinic receptor antagonist is selected from the group consisting of Atropine, Propantheline, Bethanechol, Solifenacin, Darifenacin, Tolterodine, Fesoterodine, Trospium, and Oxybutynin.

### Claim 10 (depends on 1)

The method of claim 1, wherein the muscarinic receptor antagonist is selected from the group consisting of Anisotropine, Benztropine, Biperiden, Clidinium, Cycrimine, Dicyclomine, Diphemanil, Diphenidol, Ethopropazine, Glycopyrrolate, Hexocyclium, Isopropamide, Mepenzolate, Methixene, Methscopolamine, Oxyphencyclimine, Oxyphenonium, Procyclidine, Scopolamine, Tridihexethyl and Trihexyphenidyl.

### Claim 11 (depends on 1)

The method of claim 1, wherein the muscarinic receptor antagonist is in an immediate release formulation.

### Claim 12 (depends on 1)

The method of claim 1, wherein the muscarinic receptor antagonist is in an extended release formulation.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the muscarinic receptor antagonist is Oxybutynin.

### Claim 14 (depends on 13)

The method of claim 13, wherein the Oxybutynin is administered at a dose of 2-15 mg.

### Claim 15 (depends on 14)

The method of claim 14, wherein the Oxybutynin is in an immediate release formulation with a dose of 2.5-10 mg.

### Claim 16 (depends on 14)

The method of claim 14, wherein the Oxybutynin is in an extended release formulation with a dose of 5-15 mg.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein the disease or disorder is Obstructive Sleep Apnea or Simple Snoring.

### Claim 18 (depends on 17)

The method of claim 17, wherein the disease or disorder is Obstructive Sleep Apnea.

### Claim 19 (depends on 1)

The method of claim 1, wherein the non-fully conscious state is sleep.

### Claim 20 (depends on 1)

The method of claim 1, wherein the NRI and the muscarinic receptor antagonist are administered in a single composition.

### Claim 21 (depends on 20)

The method of claim 20, wherein the single composition is an oral administration form.

### Claim 22 (depends on 21)

The method of claim 21, wherein the oral administration form is a syrup, pill, tablet, troche, or capsule.

### Claim 23

A pharmaceutical composition comprising (i) a norepinephrine reuptake inhibitor (NRI), (ii) a muscarinic receptor antagonist and (iii), in a pharmaceutically acceptable carrier.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the NRI is a norepinephrine selective reuptake inhibitor (NSRI).

### Claim 25 (depends on 24)

The composition of claim 24, wherein the NSRI is selected from the group consisting of Amedalin, Atomoxetine, CP-39,332, Daledalin, Edivoxetine, Esreboxetine, Lortalamine, Nisoxetine, Reboxetine, Talopram, Talsupram, Tandamine, and Viloxazine.

### Claim 26 (depends on 23)

The composition of claim 23, wherein the NRI is a norepinephrine non-selective reuptake inhibitor (NNRI) selected from the group consisting of Amitriptiline, Amoxapine, Bupropion, Ciclazindol, Desipramine, Desvenlafaxine, Dexmethilphenidate, Diethylpropion, Doxepin, Duloxetine, Imipramine, Levomilnacipran, Manifaxine, Maprotiline, Methylphenidate, Milnacipran, Nefazodone, Nortriptyline, Phendimetrazine, Phenmetrazine, Protryptyline, Radafaxine, Tapentadol (Nucynta), Teniloxazine (Lucelan, Metatone) and Venlafaxine.

### Claim 27 (depends on 23)

The composition of claim 23, wherein the NRI is selected from the group consisting of Atomoxetine and Reboxetine.

### Claim 28 (depends on 27)

The composition of claim 27, wherein the NRI is Atomoxetine.

### Claim 29 (depends on 28)

The composition of claim 28, wherein the dosage of Atomoxetine is 20-100 mg.

### Claim 30 (depends on 23)

The composition of claim 23, wherein the muscarinic receptor antagonist is selected from the group consisting of Atropine, Propantheline, Bethanechol, Solifenacin, Darifenacin, Tolterodine, Fesoterodine, Trospium, and Oxybutynin.

### Claim 31 (depends on 23)

The composition of claim 23, wherein the muscarinic receptor antagonist component of the pharmaceutical composition is selected from the group consisting of Anisotropine, Benztropine, Biperiden, Clidinium, Cycrimine, Dicyclomine, Diphemanil, Diphenidol, Ethopropazine, Glycopyrrolate, Hexocyclium, Isopropamide, Mepenzolate, Methixene, Methscopolamine, Oxyphencyclimine, Oxyphenonium, Procyclidine, Scopolamine, Tridihexethyl and Trihexyphenidyl.

### Claim 32 (depends on 23)

The composition of claim 23, wherein the muscarinic receptor antagonist is in an immediate release formulation.

### Claim 33 (depends on 23)

The composition of claim 23, wherein the muscarinic receptor antagonist is in an extended release formulation.

### Claim 34 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The composition of any one of claims 23-33, wherein the muscarinic receptor antagonist is Oxybutynin.

### Claim 35 (depends on 34)

The composition of claim 34, wherein the Oxybutynin is in an immediate release formulation with a dose of 2.5-10 mg.

### Claim 36 (depends on 34)

The composition of claim 34, wherein the Oxybutynin is in an extended release formulation with a dose of 5-15 mg.

### Claim 37 (depends on 23)

The composition of claim 23, wherein the NRI and the muscarinic receptor antagonist are formulated in a single composition.

### Claim 38 (depends on 37)

The composition of claim 37, wherein the single composition is an oral administration form.

### Claim 39 (depends on 38)

The composition of claim 38, wherein the oral administration form is a pill, tablet, troche, or capsule.

### Claim 40 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The composition of any one of claims 23-39, for use in treating a subject having a condition associated with pharyngeal airway collapse while the subject is in a non-fully conscious state.

### Claim 41 (depends on 40)

The composition for the use of claim 40, wherein the disease or disorder is sleep apnea or Simple Snoring.

### Claim 42 (depends on 41)

The composition for the use of claim 41, wherein the disease or disorder is Obstructive Sleep Apnea.

### Claim 43 (depends on 40)

The composition for the use of claim 40, wherein the non-fully conscious state is sleep.

### Claim 44

A norepinephrine reuptake inhibitor (NRI) and a muscarinic receptor antagonist, for use in treating a subject having a condition associated with pharyngeal airway collapse while the subject is in a non-fully conscious state.

### Claim 45

A kit comprising a norepinephrine reuptake inhibitor (NRI) and a muscarinic receptor antagonist.

### Claim 46 (depends on 41)

The kit of claim 41, for use in treating a subject having a condition associated with pharyngeal airway collapse while the subject is in a non-fully conscious state.
